<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01100645</url>
  </required_header>
  <id_info>
    <org_study_id>VCPEMS0210</org_study_id>
    <secondary_id>Version 2</secondary_id>
    <nct_id>NCT01100645</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A in Patients With Psychophysiological Insomnia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the clinical efficacy of the drug Sominex
      (Valeriana officinalis L., 40 mg, 30 mg Crataegus oxyacantha L. and Passiflora incarnata L.
      50 mg) manufactured by the Laboratory EMS S / A, compared to placebo in improving sleep
      efficiency, based on the response of the sleep quality questionnaire (MSQ) and
      polysomnographic parameters described below:

        -  Latency to onset of sleep;

        -  Total time of sleep;

        -  Rapid eye movement (REM) sleep latency;

        -  Duration of REM sleep
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Verify the effectiveness of the drug Sominex compared to placebo based on the improvement of
      the following parameters measured by the following validated scales:

        -  Anxiety;

        -  Daytime sleepiness; Will also be assessed secondary to drug safety testing for the
           occurrence, type, frequency and intensity of adverse events during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in sleep efficiency</measure>
    <time_frame>28 days of treatment.</time_frame>
    <description>Quality of Sleep Questionnaire and the polysomnographic parameters:
Latency to onset of sleep;
Total time of sleep;
REM sleep latency;
Duration of REM sleep;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of the values obtained by the answers of the questionnaires obtained during the treatment</measure>
    <time_frame>28 days of treatment.</time_frame>
    <description>Scale Hamilton Anxiety (HAM-A); Daytime Sleepiness Scale Epworth; Journal of Sleep</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sominex</intervention_name>
    <description>Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Excipient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who agree and sign the informed consent form (ICF);

          2. Adult patients, aged ≥ 18 years and ≤ 65 years, male or female;

          3. Patients who agree to perform all study procedures;

          4. Patients diagnosed with psychophysiological insomnia;

          5. Patients who present in the application of sleep questionnaire result ≥ 25 and ≤ 30
             points;

          6. Patients presenting in polysomnography change in any of the polysomnographic
             parameters than the normal range.

        Exclusion Criteria:

          1. Having participated in any experimental study or have ingested any drug trial within
             12 months prior to the start of the study;

          2. Be in use or have used other medications that interfere with the regular response of
             the drug at least 04 weeks prior to the start of the study, as benzodiazeínicos,
             antidepressants with sedative, sedatives, antihistamines and other herbal medicines;

          3. Being in treating or have been treated with alternative methods that interfere with
             the drug response to at least 04 weeks prior to the start of the study, such as
             behavioral therapies and relaxation techniques, such as yoga, massage, etc.;

          4. Be patient with sensitivity to an association of herbal medicines;

          5. Present history of alcohol abuse, drugs or medicines;

          6. Pregnant or nursing women;

          7. Owning a history of liver disease or renal impairment and / or thyroid dysfunction;

          8. Patients with a history of restless sleep: nocturnal myoclonus or restless legs
             syndrome;

          9. Patients with a history of snoring or bruxism exaggerated;

         10. Diseases that affect sleep, causing pain or immobilization of the patient in bed;

         11. Patients who have extensive work or working in night shifts totally or partially
             nocturnal;

         12. Patients in whom polysomnography demonstrating non-characteristic changes in sleep
             disturbances of psychophysiological origin as narcolepsy, hipopinéia syndrome, upper
             airway hypersensitivity syndrome of periodic limb movements, sleepwalking, among
             others;

         13. Physical or psychological disorders that might interfere with the analysis of data
             such as neurosis, depression, muscle atrophy, and / or staying the medical criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LAL Clinica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre Frederico</last_name>
      <phone>+55 19 3871-6399</phone>
      <email>alexandre@lalclinica.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clínica Pesquisa e Desenvolvimento Ltda.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

